<DOC>
	<DOCNO>NCT00831025</DOCNO>
	<brief_summary>The objective trial ass clinical efficacy modify allergen extract Olea europaea pollen treatment patient affect allergic rhinitis/rhinoconjunctivitis ( without episodic asthma ) induce hypersensitivity olea europaea pollen , evaluate Score regard Symptoms consumption medication .</brief_summary>
	<brief_title>Subcutaneous Immunotherapy Treatment Patients With Hypersensitivity Olea Europaea Pollen</brief_title>
	<detailed_description>Immunotherapy specific treatment allergic disease . Unlike conventional pharmacological treatment , immunotherapy treatment could modify natural course allergic disease . This prospective double-blind placebo-controlled study two arm treatment : placebo active .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Prior study specific examination patient applicable legal guardian give his/her write informed consent Patients gender age 18 55 year Patient ` perception disease activity least 30 mm 100 mm visual analogue scale ( VAS ) FEV1 great equal 80 % expect value , , improvement FEV1 great 12 % bronchodilation Patients suffer allergic complaint ( rhinitis and/or rhinoconjunctivitis without mild intermittent allergic asthma ) cause clinical sensitization Olea europaea pollen . The IgE mediate sensitization verify : Suggestive medical history Specific IgE Olea europaea pollen CAP RAST ≥0.7Ku/l Positive skin prick test ( SPT ) grass Olea pollen result wheal diameter least 3 mm . Exclusion Criteria History significant clinical manifestation allergy result sensitization weed pollen allergen perennial ( e.g . house dust mite . Participation immunotherapy comparable extract within last five year . Treatment βblocker Any disease prohibits use adrenaline ( e.g . hyperthyroidism ) Cardiovascular insufficiency severe unstable pulmonary , endocrine disease ; clinically significant renal hepatic disease dysfunction ; hematologic disorder ; clinically significant medical condition could increase risk study participant Immunopathological diseases Patients expect noncompliant and/or cooperative Women , pregnancy define state female conception termination gestation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Allergoid</keyword>
	<keyword>Depigmented</keyword>
	<keyword>Polymerized</keyword>
	<keyword>Allergen-extract</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>